Alkermes, Inc. is a fully-integrated global biopharmaceutical company headquartered in Ireland, with additional operations in Massachusetts and Ohio. The company specializes in developing innovative medicines that address complex psychiatric and neurological disorders, including alcohol and opioid dependence, schizophrenia, and bipolar disorder, leveraging its deep neuroscience expertise. Alkermes is committed to fostering a culture of diversity, inclusion, and belonging, believing that a diverse workforce enhances its mission to make a meaningful impact on patients' lives. Recognized as a Great Place to Work in 2024 and acknowledged for its commitment to workplace mental health, Alkermes stands out as a leader in excellence and innovation within the healthcare sector.